AnaptysBio Inc

NASDAQ:ANABUnited States

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Contact Information

Headquarters

10770 WATERIDGE CIRCLE, SUITE 210SAN DIEGO, CA, United States 92121

Phone

858-362-6295

Fax

858-362-6296

Executives

Chairman of the Board

John Orwin

President, Chief Executive Officer, Director

Daniel Faga

Chief Financial Officer

Dennis Mulroy

Chief Medical Officer

Paul Lizzul

Chief Legal Officer

Eric Loumeau